Literature DB >> 21900290

Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes.

Qibin Qi1, Tsegaselassie Workalemahu, Cuilin Zhang, Frank B Hu, Lu Qi.   

Abstract

AIMS: To examine the relations between genetic loci, plasma lipoprotein(a) [Lp(a)] levels, and cardiovascular disease (CVD) risk among diabetic patients and compare with the observations in the general population. METHODS AND
RESULTS: In two prospective cohorts of patients with type 2 diabetes (n= 2308) from the Nurses' Health Study and the Health Professional Follow-Up Study, we performed (i) genome-wide association (GWA) scans for plasma Lp(a); (ii) prospective analysis of plasma Lp(a) for CVD risk and mortality; and (iii) genetic association analysis for CVD risk and mortality. Meta-analysis of the two GWA scans yielded 71 single-nucleotide polymorphisms (SNPs) on chromosome 6q associated with plasma Lp(a) levels at a genome-wide significance level (P< 5 × 10(-8)). The SNP rs10455872 in LPA was most strongly associated with Lp(a) (P= 4.60 × 10(-39)). Forward-selection analysis indicated that rs10455872 and other five SNPs in a region encompassing LPA, PLG, SLC22A3, and LPAL2 genes were independently associated with Lp(a) levels and jointly explained ∼20% of variation in diabetic patients. In prospective analysis, we did not find any significant association between plasma levels and CVD incidence; the relative risk for coronary heart disease (CHD), CVD, and CVD death was 1.05 [95% confidence interval (CI): 0.95-1.15], 1.05 (0.96-1.15), and 1.21 (0.99-1.47) per 1-SD higher log-transformed Lp(a) levels, respectively. Consistently, none of the Lp(a) SNPs were associated with CVD risk or mortality (all P> 0.09). For the best SNP rs10455872 for plasma Lp(a) levels, the OR for CHD, CVD, and CVD death was 0.94 (95% CI: 0.69-1.28), 0.97 (0.72-1.29), and 1.23 (0.79-1.92), respectively. The genetic effect on CHD risk showed a significant heterogeneity between the diabetic and the general populations (P= 0.006).
CONCLUSION: Our data indicate that the effect of Lp(a) on CVD risk among diabetic patients might be different from that in the general population. Diabetes status may attenuate the relation between Lp(a) and cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21900290      PMCID: PMC3270044          DOI: 10.1093/eurheartj/ehr350

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  46 in total

Review 1.  Lipoprotein(a): intrigues and insights.

Authors:  H H Hobbs; A L White
Journal:  Curr Opin Lipidol       Date:  1999-06       Impact factor: 4.776

2.  Lipoprotein(a) as a risk factor for cardiovascular mortality in type 2 diabetic patients: a 10-year follow-up study.

Authors:  Cristina Hernández; Gemma Francisco; Pilar Chacón; Rafael Simó
Journal:  Diabetes Care       Date:  2005-04       Impact factor: 19.112

3.  Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?

Authors:  Heinz Drexel; Stefan Aczel; Thomas Marte; Werner Benzer; Peter Langer; Willi Moll; Christoph H Saely
Journal:  Diabetes Care       Date:  2005-01       Impact factor: 19.112

4.  Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients.

Authors:  C H Saely; L Koch; F Schmid; T Marte; S Aczel; P Langer; G Hoefle; H Drexel
Journal:  Eur J Clin Invest       Date:  2006-02       Impact factor: 4.686

5.  Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease.

Authors:  Laurence Tiret; Tiphaine Godefroy; Edith Lubos; Viviane Nicaud; David-Alexandre Tregouet; Sandrine Barbaux; Renate Schnabel; Christoph Bickel; Christine Espinola-Klein; Odette Poirier; Claire Perret; Thomas Münzel; Hans-Jurgen Rupprecht; Karl Lackner; François Cambien; Stefan Blankenberg
Journal:  Circulation       Date:  2005-07-25       Impact factor: 29.690

6.  The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients.

Authors:  Christoph H Saely; Stefan Aczel; Thomas Marte; Peter Langer; Guenter Hoefle; Heinz Drexel
Journal:  J Clin Endocrinol Metab       Date:  2005-08-09       Impact factor: 5.958

7.  Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN).

Authors:  Karen A Matthews; Mary Fran Sowers; Carol A Derby; Evan Stein; Heidi Miracle-McMahill; Sybil L Crawford; Richard C Pasternak
Journal:  Am Heart J       Date:  2005-06       Impact factor: 4.749

8.  A prospective study of lipoprotein(a) and risk of coronary heart disease among women with type 2 diabetes.

Authors:  I Shai; M B Schulze; J E Manson; M J Stampfer; N Rifai; F B Hu
Journal:  Diabetologia       Date:  2005-06-22       Impact factor: 10.122

9.  The +276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic men.

Authors:  Lu Qi; Tricia Li; Eric Rimm; Cuilin Zhang; Nader Rifai; David Hunter; Alessandro Doria; Frank B Hu
Journal:  Diabetes       Date:  2005-05       Impact factor: 9.461

10.  Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype.

Authors:  D L Rainwater; S M Haffner
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-08       Impact factor: 8.311

View more
  36 in total

1.  A genome-wide association study on lipoprotein (a) levels and coronary artery disease severity in a Chinese population.

Authors:  Yibin Liu; Hongkun Ma; Qian Zhu; Bin Zhang; Hong Yan; Hanping Li; Jinxiu Meng; Weihua Lai; Liwen Li; Danqing Yu; Shilong Zhong
Journal:  J Lipid Res       Date:  2019-06-11       Impact factor: 5.922

2.  Practical Approaches for Whole-Genome Sequence Analysis of Heart- and Blood-Related Traits.

Authors:  Alanna C Morrison; Zhuoyi Huang; Bing Yu; Ginger Metcalf; Xiaoming Liu; Christie Ballantyne; Josef Coresh; Fuli Yu; Donna Muzny; Elena Feofanova; Navin Rustagi; Richard Gibbs; Eric Boerwinkle
Journal:  Am J Hum Genet       Date:  2017-01-12       Impact factor: 11.025

3.  A solute carrier family 22 member 3 variant rs3088442 G→A associated with coronary heart disease inhibits lipopolysaccharide-induced inflammatory response.

Authors:  Lu Li; Meian He; Li Zhou; Xiaoping Miao; Fangqing Wu; Suli Huang; Xiayun Dai; Tian Wang; Tangchun Wu
Journal:  J Biol Chem       Date:  2015-01-05       Impact factor: 5.157

4.  Genetic variants in PLG, LPA, and SIGLEC 14 as well as smoking contribute to plasma plasminogen levels.

Authors:  Qianyi Ma; Ayse B Ozel; Shweta Ramdas; Beth McGee; Rami Khoriaty; David Siemieniak; Hong-Dong Li; Yuanfang Guan; Lawrence C Brody; James L Mills; Anne M Molloy; David Ginsburg; Jun Z Li; Karl C Desch
Journal:  Blood       Date:  2014-09-10       Impact factor: 22.113

5.  Lipoprotein(a), type 2 diabetes and nephropathy; the mystery continues.

Authors:  Azar Baradaran
Journal:  J Nephropathol       Date:  2012-10-01

6.  Cardiovascular Disease, Mortality Risk, and Healthcare Costs by Lipoprotein(a) Levels According to Low-density Lipoprotein Cholesterol Levels in Older High-risk Adults.

Authors:  Yanglu Zhao; Joseph A Delaney; Ruben G W Quek; Julius M Gardin; Calvin H Hirsch; Shravanthi R Gandra; Nathan D Wong
Journal:  Clin Cardiol       Date:  2016-05-13       Impact factor: 2.882

Review 7.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

8.  Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options.

Authors:  Andreja Rehberger Likozar; Mark Zavrtanik; Miran Šebeštjen
Journal:  Ann Med       Date:  2020-06-08       Impact factor: 4.709

Review 9.  Putting the Genome in Context: Gene-Environment Interactions in Type 2 Diabetes.

Authors:  Paul W Franks; Guillaume Paré
Journal:  Curr Diab Rep       Date:  2016-07       Impact factor: 4.810

10.  Normal thyroid-stimulating hormone levels, autoimmune activation, and coronary heart disease risk.

Authors:  Altan Onat; Mesut Aydın; Günay Can; Etem Çelik; Servet Altay; Ahmet Karagöz; Evin Ademoğlu
Journal:  Endocrine       Date:  2014-05-03       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.